




OUTSOURCING

Key Players in Pharmaceutical Contract Manufacturing

Market developments, outsourcing hotspots and growth strategies

 [Table of Contents](#)

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any
purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of
Business Insights. Business Insights Ltd accepts no liability for the accuracy or
completeness of the information, advice or comment contained in this Management
Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of
publication, no responsibility can be accepted by Business Insights Ltd for its
completeness or accuracy.

Table of Contents

Key Players in Pharmaceutical Contract Manufacturing

Executive summary	12
Market development	12
Catalent	12
Lonza	13
Boehringer Ingelheim (BI)	14
DSM	15
Evonik	15
Patheon	16
Piramal	17
Jubilant	17
Aenova	18
Fareva	19
Chapter 1 Introduction	22
What is this report about?	22
Methodology	22
Chapter 2 Market development	26
Summary	26
Overview	27
Market size and growth	27
Positioning and performance of leading players	27
Drivers of manufacturing outsourcing	29
Key trends in the market	30
Increasing offshore outsourcing by Big Pharma	30
Expansion of biopharmaceutical contract manufacturing	30
Industry consolidation	31

Contract manufacturing hotspots – India and China	32
India	32
Contract manufacturing in India	33
Key CMOs in India	33
China	35
Contract Manufacturing in China	36
Key CMOs in China	36
Comparison of India and China on key parameters	38
Availability of skilled labor	38
Cost	39
Manufacturing infrastructure	40
Global capabilities	41
Service portfolio	41
Concerns about offshoring	42

Chapter 3 Catalent 44

Summary	44
Company overview	45
Group structure	45
Oral Technologies	45
Sterile Technologies	45
Packaging Services	46
Recent financial performance	46
Performance by business segments	47
Oral Technologies	47
Sterile Technologies	48
Packaging Services	48
Performance by geographies	49
Manufacturing and R&D	50
Acquisitions and divestments	50
Growth strategies	51

Chapter 4 Lonza 54

Summary	54
Company overview	55
Group structure	55
Life Science Ingredients	55
Exclusive Synthesis & Biopharmaceuticals	55
Bioscience	56
Recent financial performance	56

Performance by business segments	58
Manufacturing and R&D	58
Acquisitions and divestments	59
Growth strategies	60
Capacity expansion	60
Strategic partnerships and acquisitions	60
High value products	61
Chapter 5	Boehringer Ingelheim (BI)
	64
Summary	64
Company overview	65
Group structure	65
Biopharmaceuticals	65
Pharmaceuticals Production	66
Pharma Chemicals	66
Recent financial performance	66
Performance by business segments	67
Manufacturing and R&D	68
Acquisitions and divestments	69
Growth strategies	69
Capacity expansion	69
Strategic partnerships	69
Chapter 6	Royal DSM (DSM)
	72
Summary	72
Company overview	73
Group structure	73
Recent financial performance	74
Manufacturing and R&D	76
Acquisitions and divestments	76
Growth strategies	77
Chapter 7	Evonik (Degussa)
	80
Summary	80

Company overview	81
Group structure	81
Recent financial performance	82
Manufacturing and R&D	84
Acquisitions and divestments	84
Growth strategies	85
Restructuring of operations	85
Geographic restructuring	85
Capacity expansion	86
Geographic expansion	86
Chapter 8	Patheon
	88
Summary	88
Company overview	89
Group structure	89
Commercial Manufacturing	89
Pharmaceutical Development Services (PDS)	89
Recent financial performance	90
Performance by business segments	91
Performance by geographies	92
Manufacturing and R&D	93
Acquisitions and divestments	93
Growth strategies	94
Focus on prescription drugs business	94
Improve profitability and capacity utilization	94
Diversify customer base	94
Chapter 9	Piramal Healthcare (Piramal)
	96
Summary	96
Company overview	97
Group structure	97
PDS (Pharmaceutical Development Services)	97
PMS (Pharmaceutical Manufacturing Services)	98
MMBB (Manufacturing Molecules/ Building Blocks)	98
Others	98
Recent financial performance	98
Performance by business segments	100
Manufacturing and R&D	100

Acquisitions and divestments	101
Growth strategies	101
Chapter 10	Jubilant Organosys (Jubilant) 104
Summary	104
Company overview	105
Group structure	105
Recent financial performance	106
Performance by product segments	107
Performance by geographies	108
Manufacturing and R&D	110
Acquisitions and divestments	110
Growth strategies	111
Chapter 11	Aenova 114
Summary	114
Company overview	115
Group structure	115
Swiss Caps	115
Dragenopharm	115
Recent financial performance	116
Manufacturing and R&D	116
Acquisitions and divestments	117
Growth strategies	117
Chapter 12	Fareva 120
Summary	120
Company overview	121
Group structure	121
Recent financial performance	122
Manufacturing and R&D	123
Acquisitions and divestments	123
Growth strategies	124

Chapter 13 11 to 20 Companies 126

Nipro	126
Company overview	126
Recent financial performance	127
Siegfried	128
Company description	128
Recent financial performance	129
Haupt	130
Company description	130
Recent financial performance	131
Divi's Laboratories (Divi's)	132
Company description	132
Recent financial performance	133
Cambrex	134
Company description	134
Recent financial performance	134
Recipharm	135
Company description	135
Recent financial performance	136
Archimica	137
Company description	137
Vetter	138
Company description	138
Famar	139
Company description	139
NextPharma	141
Company description	141
Other contract manufacturers	142
Index	143

List of Figures

Figure 2.1:	Global pharmaceutical contract manufacturing market size, 2007-2011	27
Figure 2.2:	Positioning of leading players (2007)*	29
Figure 2.3:	Labor cost in select countries	39
Figure 2.4:	No. of FDA approved plants outside the US, 2007	41
Figure 3.5:	Catalent's financial performance (\$m), 2004-2008*	47
Figure 3.6:	Catalent's revenue break-up by geography (%), 2008	49
Figure 4.7:	Lonza's contract manufacturing financial performance (\$m), 2005-2007*	57
Figure 5.8:	BI Industrial Customers' financial performance (\$m), 2005-2007*	67
Figure 6.9:	DSM DPP's financial performance (\$m), 2005-2007*	75
Figure 7.10:	Evonik's Health & Nutrition financial performance (\$m), 2006-2007*	83
Figure 8.11:	Patheon's financial performance (\$m), 2006-2008*	90
Figure 8.12:	Patheon's Commercial Manufacturing revenue break-up by geography (%), 2008*	92
Figure 9.13:	Piramal Pharma Solutions' financial performance (\$m), 2006-2007*	99
Figure 10.14:	Jubilant's CRAMS financial performance (\$m), 2003-2007*	107
Figure 10.15:	Jubilant's revenue break-up by geography (%), 2007*	109
Figure 12.16:	Fareva Pharmaceuticals' financial performance (\$m), 2006-2008*	122

List of Tables

Table 2.1:	Leading pharmaceutical contract manufacturing companies, 2007	28
Table 2.2:	Select manufacturing outsourcing initiatives planned by the Big Pharma	30
Table 2.3:	Leading CMOs in India	34
Table 2.4:	Select foreign acquisitions by Indian players	35
Table 2.5:	Manufacturing cost comparison	40
Table 3.6:	Catalent's snapshot	44
Table 3.7:	Catalent's financial performance (\$m), 2004-2008	47
Table 3.8:	Catalent's business segments performance (\$m), 2006-2008	48
Table 3.9:	Catalent's performance by geography (\$m), 2006-2008	49
Table 4.10:	Lonza's snapshot	54
Table 4.11:	Lonza's contract manufacturing financial performance (\$m), 2005-2007	57
Table 4.12:	Lonza's contract manufacturing business segments performance (\$m), 2005-2007	58
Table 5.13:	BI's snapshot	64
Table 5.14:	BI Industrial Customers' financial performance (\$m), 2005-2007	67
Table 5.15:	BI Industrial Customers' business segments performance (\$m), 2005-2007	68
Table 6.16:	DSM's snapshot	72
Table 6.17:	DSM DPP's financial performance (\$m), 2005-2007	75
Table 7.18:	Evonik's snapshot	80
Table 7.19:	Evonik's Health & Nutrition financial performance (\$m), 2006-2007	83
Table 8.20:	Patheon's snapshot	88
Table 8.21:	Patheon's financial performance (\$m), 2006-2008	91
Table 8.22:	Patheon's business segments performance (\$m), 2008	91

Table 8.23:	Patheon's Commercial Manufacturing performance by geography (\$m), 2007–2008	93
Table 9.24:	Piramal's snapshot	96
Table 9.25:	Piramal Pharma Solutions' financial performance (\$m), 2006-2007	99
Table 9.26:	Piramal Pharma Solutions' business segments performance (\$m), 2005-2007	100
Table 10.27:	Jubilant's snapshot	104
Table 10.28:	Jubilant's CRAMS financial performance (\$m), 2003-2007	107
Table 10.29:	Jubilant's CRAMS product segments performance (\$m), 2006-2007	108
Table 10.30:	Jubilant's performance by geography (\$m), 2005–2007	109
Table 11.31:	Aenova's snapshot	114
Table 12.32:	Fareva's snapshot	120
Table 12.33:	Fareva Pharmaceuticals' financial performance (\$m), 2006-2008	123
Table 13.34:	Nipro's snapshot	126
Table 13.35:	Nipro's Pharmaceutical financial performance (\$m), 2003-2007 *	127
Table 13.36:	Siegfried's snapshot	128
Table 13.37:	Siegfried's financial performance (\$m), 2006-2007*	129
Table 13.38:	Haupt's snapshot	130
Table 13.39:	Divi's snapshot	132
Table 13.40:	Divi's financial performance (\$m), 2003-2007	133
Table 13.41:	Cambrex's snapshot	134
Table 13.42:	Cambrex's financial performance (\$m), 2005-2007*	135
Table 13.43:	Recipharm's snapshot	135
Table 13.44:	Recipharm's financial performance (\$m), 2003-2008	136
Table 13.45:	Archimica's snapshot	137
Table 13.46:	Vetter's snapshot	138
Table 13.47:	Famar's snapshot	139
Table 13.48:	NextPharma's snapshot	141
Table 13.49:	Other select contract manufacturers	142